ENGI-002

ENGI-002 is an investigational soluble T‑cell receptor (TCR)–based biologic being developed by Engimmune Therapeutics as part of its pipeline of engineered, off‑the‑shelf TCR therapies for solid tumors. Engimmune specializes in high‑affinity, highly specific TCR molecules and related formats (including agonistic and inhibitory specTRs) designed to recognize peptide–HLA complexes on tumor cells, with ENGI-002 representing one of its early, preclinical candidates in oncology. Publicly available sources list ENGI-002 only as a pipeline code name without detailed disclosure of its precise target, construct design, or lead indication, but it is expected to follow the company’s core strategy of using protein engineering to generate potent, selective T cell–redirecting or TCR-mimetic agents for cancer immunotherapy.